Comment on “Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials”
Comment on “Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials”. // International Journal of Cardiology Cardiovascular Risk and Prevention. – URL: https://www.sciencedirect.com/science/article/pii/S2772487526001248?dgcid=rss_sd_all
Comment on “Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials”. International Journal of Cardiology Cardiovascular Risk and Prevention. https://www.sciencedirect.com/science/article/pii/S2772487526001248?dgcid=rss_sd_all
“Comment on “Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials”.” International Journal of Cardiology Cardiovascular Risk and Prevention.
@article{article49227,
title = {Comment on “Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials”},
journal = {International Journal of Cardiology Cardiovascular Risk and Prevention},
url = {https://www.sciencedirect.com/science/article/pii/S2772487526001248?dgcid=rss_sd_all}
}
Abstract Background Macrophage polarisation plays a crucial role in sepsis‐associated inflammatory responses; however, the underlying molecular regulatory mechanisms remain to be further explored. Aim This study aimed to explore the...